Carboplatin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In oncology, '''carboplatin''' is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref> ==History== In the United States, it was approved with a [htt...) |
imported>Howard C. Berkowitz No edit summary |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
In [[oncology]], '''carboplatin''' is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref> | {{subpages}} | ||
{{TOC|right}} | |||
In [[oncology]], '''carboplatin''' is a [[antineoplastic agent]] that is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref> As compared to [[cisplatin]], carboplatin has equal ([[lung cancer]], [[ovarian cancer]]) or less ([[germ cell tumor]]s, [[bladder cancer]], [[head and neck cancer]]) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> When considered in veterinary oncology, carboplatin can be used in cats but cisplatin is fatal to felines. | |||
Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the [[World Health Organization]] calls "other neoplastic agents", specifically class L01XA. <ref>WHO drug database search tool, [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XA]</ref> | |||
==History== | ==History== | ||
In the United States, it was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1989.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=019880 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076039 Drugs@FDA]. U S Food and Drug Administration</ref> | In the United States, it was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1989.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=019880 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076039 Drugs@FDA]. U S Food and Drug Administration</ref> | ||
==Indications== | |||
===Human=== | |||
In the U.S., it is only approved for [[ovarian carcinoma]], but common off-label uses include:<ref>{{citation | |||
| url = http://www.medscape.com/druginfo/dosage?drugid=4551&drugname=Carboplatin+IV&monotype=default | |||
| title = Carboplatin | |||
| publisher = American Society of Health System Pharmacists}}</ref> | |||
*[[carcinoma]]s | |||
**[[endometrial carcinoma]] | |||
**[[neuroendocrine prostate carcinoma]] | |||
**[[small cell lung carcinoma]] | |||
**metastatic and locally advanced [[breast carcinoma]] | |||
*[[leukemia]]s | |||
** [[acute myeloid leukemia]] | |||
*Unspecified histology | |||
**Malignant Tumor of Cervix | |||
**Malignant Tumor of Head and Neck | |||
**Malignant Tumor of Urinary Bladder | |||
**Non-Small Cell Lung Cancer | |||
**Refractory Malignant Tumor of Testis | |||
*Lymphoma | |||
**Progressive Diffuse Large B-Cell Lymphoma | |||
*[[Sarcoma]] | |||
**Refractory [[Ewing's sarcoma]] | |||
**Refractory [[osteosarcoma]] | |||
*Seminoma of Testis, | |||
===Veterinary=== | |||
It is usually the second chemotherapeutic agent used in [[feline squamous cell carcinoma]]. | |||
==Dosage== | |||
Carboplatin may be dosed by the Calvert formula:<ref name="pmid2681557">{{cite journal| author=Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al.| title=Carboplatin dosage: prospective evaluation of a simple formula based on renal function. | journal=J Clin Oncol | year= 1989 | volume= 7 | issue= 11 | pages= 1748-56 | pmid=2681557 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=2681557 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | |||
:<math>Dose\ (mg)\ =\ target\ AUC \times\ (GFR + 25)</math> | |||
==External links== | ==External links== | ||
| Line 8: | Line 44: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
Latest revision as of 08:06, 27 June 2010
In oncology, carboplatin is a antineoplastic agent that is an "organoplatinum compound that possesses antineoplastic activity."[1] As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2] When considered in veterinary oncology, carboplatin can be used in cats but cisplatin is fatal to felines.
Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the World Health Organization calls "other neoplastic agents", specifically class L01XA. [3]
History
In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[4] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[5]
Indications
Human
In the U.S., it is only approved for ovarian carcinoma, but common off-label uses include:[6]
- carcinomas
- endometrial carcinoma
- neuroendocrine prostate carcinoma
- small cell lung carcinoma
- metastatic and locally advanced breast carcinoma
- leukemias
- Unspecified histology
- Malignant Tumor of Cervix
- Malignant Tumor of Head and Neck
- Malignant Tumor of Urinary Bladder
- Non-Small Cell Lung Cancer
- Refractory Malignant Tumor of Testis
- Lymphoma
- Progressive Diffuse Large B-Cell Lymphoma
- Sarcoma
- Refractory Ewing's sarcoma
- Refractory osteosarcoma
- Seminoma of Testis,
Veterinary
It is usually the second chemotherapeutic agent used in feline squamous cell carcinoma.
Dosage
Carboplatin may be dosed by the Calvert formula:[7]
External links
The most up-to-date information about Carboplatin and other drugs can be found at the following sites.
- Carboplatin - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Carboplatin - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Carboplatin - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
- ↑ WHO drug database search tool, [1]
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Carboplatin, American Society of Health System Pharmacists
- ↑ Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. (1989). "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.". J Clin Oncol 7 (11): 1748-56. PMID 2681557.